Management ChangeApr 30, 2026, 05:17 PM
PCSA CDRO Sian Bigora transitions to part-time; 2025 Executive Comp
AI Summary
Processa Pharmaceuticals, Inc. filed an amendment to its 10-K, announcing that Dr. Sian Bigora will transition from full-time Chief Development and Regulatory Officer to a part-time employee role effective May 1, 2026, and will no longer be an executive officer. The filing also detailed executive compensation for 2024 and 2025, with CEO George Ng receiving $673,303 in 2025, and provided updated employment agreements and board committee compositions.
Key Highlights
- Dr. Sian Bigora will transition from full-time Chief Development and Regulatory Officer to a part-time employee role effective May 1, 2026.
- George Ng (CEO) total compensation was $673,303 in 2025 and $521,033 in 2024.
- Russell Skibsted (CFO) total compensation was $566,760 in 2025 and $244,226 in 2024.
- Sian Bigora (CDRO) total compensation was $495,097 in 2025 and $328,251 in 2024.
- Company granted stock options for 55,200 shares (value ~$267,000) and RSUs for 18,400 shares (value ~$91,000) in 2025.
- Executive employment agreements updated with base salaries ranging from $325,520 to $400,000.
- Board of Directors consists of six members, with four independent directors.
Price Impact
More from PCSA